Mylan Begins Sale of Generic Aciphex

Mylan Begins Sale of Generic Aciphex

A unit of Mylan is rolling out what it surely hopes will be a popular generic version of a name-brand drug. The company said its Mylan Pharmaceuticals has launched Rabeprazole Sodium Delayed-release Tablets, a version of the branded Aciphex manufactured by Japanese drug maker Eisai.

Rabeprazole sodium is used for the short-term treatment of erosive or ulcerative gastroesophageal reflux disease, and for duodenal ulcers, in patients aged 12 and above. The former is described by the Food and Drug Administration as "a common condition in which the backward flow of acid from the stomach causes heartburn and possible injury to the esophagus."

In addition to Mylan Pharmaceuticals, Dr. Reddy's Laboratories, Kremers Urban Pharmaceuticals, Lupin Pharmaceuticals, Teva USA, and Torrent Pharmaceuticals all received final approval by the FDA last week to sell their versions of the medication.

The article Mylan Begins Sale of Generic Aciphex originally appeared on

Fool contributor Eric Volkman and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published